Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Core Insights - Skye Bioscience, Inc. has shared interim data from the Phase 2a CBeyond study of nimacimab, a negative allosteric modulating antibody targeting obesity, in combination with a GLP-1R agonist, semaglutide [1][2] Interim Data Summary - The extension phase of the CBeyond study for combination cohorts began in May 2025, with participants receiving either nimacimab plus semaglutide or placebo plus semaglutide [2] - In the nimacimab plus semaglutide arm, participants experienced a mean weight loss of 14.4% at 26 weeks [2] - Seven participants in the nimacimab plus semaglutide arm completed an additional 26 weeks, achieving a total mean weight loss of 22.3% after 52 weeks, with no weight loss plateau observed [3] Safety and Tolerability - The combination therapy of nimacimab and semaglutide demonstrated safety and was well-tolerated, with no serious adverse events reported during the extension period [3] Placebo Group Results - In the placebo plus semaglutide arm, participants had a mean weight loss of 13.9% at 26 weeks, and those who completed the additional 26 weeks lost an additional 5.8%, resulting in a total mean weight loss of 19.7% after 52 weeks [4] Comparison of Treatment Efficacy - Top-line data indicated that the combination of nimacimab and semaglutide achieved a clinically meaningful weight loss of -13.2% compared to -10.25% for semaglutide alone, with no plateau observed [5] - The nimacimab monotherapy did not meet the primary endpoint, showing a weight loss of -1.52% compared to -0.26% for placebo [5] Weight Regain Analysis - Participants treated with nimacimab + semaglutide regained only 17.8% of their weight loss at 26 weeks during a 13-week off-therapy follow-up, indicating a potential durable response [6] - In contrast, those on semaglutide alone experienced a weight regain of 37.3% from the weight lost at 26 weeks [6] Future Expectations - Topline data from the CBeyond Phase 2a extension, including monotherapy data and follow-up results, is anticipated in the third quarter of 2026 [7] Analyst Perspective - Analysts from William Blair noted that with a cash runway extending into the fourth quarter of 2026, further analysis of the Phase 2a study could attract investor interest, contingent on supportive data regarding the exposure/weight loss relationship [8] - At the time of publication, Skye Bioscience shares were down 5.53% to $0.95 [8]